11.1 Recognition of Classic Toxidromes and Vital Sign Pattern Analysis

In acute poisoning, obtaining a reliable exposure history is frequently hindered by altered mental status, patient obfuscation, or unwitnessed circumstances. Consequently, clinical toxicology relies heavily on the toxidrome (toxic syndrome)—a constellations of clinical signs, symptoms, and physiological perturbations characteristic of a specific pharmacological class. Recognizing a toxidrome allows the Specialist in Poison Information (CSPI) and bedside clinician to narrow diagnostic differentials, anticipate life-threatening complications, initiate targeted supportive care, and administer specific antidotes before analytical laboratory results are available.

---

The Five Classic Toxidromes

The five cardinal toxidromes encountered in clinical practice reflect major disruptions across the central and autonomic nervous systems.

Autonomic / Central Disruption Spectrum:
Sympathomimetic:    [Tachycardia, Hypertension, Hyperthermia, Mydriasis, DIAPHORETIC, Active Bowel]
Anticholinergic:    [Tachycardia, Hypertension, Hyperthermia, Mydriasis, ANHIDROTIC, Urinary Retention]
Cholinergic:        [Bradycardia/Tachycardia, Miosis, Excessive Secretions (SLUDGEM/Killer B's)]
Opioid:             [Bradypnea, Bradycardia, Hypotension, Hypothermia, Miosis, Coma]
Sedative-Hypnotic:  [Depressed Consciousness, Normal Pupils, Normal/Mild Vitals Depression, Ataxia]

1. Anticholinergic (Antimuscarinic) Toxidrome

Anticholinergic toxicity results from competitive antagonism at central and peripheral muscarinic acetylcholine receptors (M₁ through M₅). Nicotinic receptors are unaffected.

• Offending Agents: First-generation antihistamines (diphenhydramine, hydroxyzine, chlorpheniramine), tricyclic antidepressants (amitriptyline, nortriptyline), belladonna alkaloids (atropine, scopolamine, hyoscyamine), plants (Datura stramonium [Jimson weed], Atropa belladonna [deadly nightshade]), antipsychotics (quetiapine, olanzapine, clozapine), antiparkinsonian antimuscarinics (benztropine, trihexyphenidyl), and antispasmodics (oxybutynin, dicyclomine).
• Pathophysiological Manifestations:
  • Central: Agitated delirium, nonsensical muttering speech, purposeless reaching and grasping movements (carphologia and floccillation), auditory and visual hallucinations, disorientation, seizures, and hyperpyrexia.
  • Peripheral: Sinus tachycardia (blockade of vagal cardiac muscarinic M₂ receptors), cutaneous vasodilation leading to flushed red skin ('red as a beet'), profound anhidrosis with dry mucous membranes and parched axillae ('dry as a bone'), mydriasis with cycloplegia causing blurred near vision ('blind as a bat'), gastrointestinal hypomotility with diminished or absent bowel sounds, and urinary bladder distension with acute urinary retention ('full as a flask').

2. Cholinergic Toxidrome

Cholinergic toxicity arises from an excessive accumulation of acetylcholine at muscarinic, nicotinic, and central neural receptor sites, typically caused by inhibition of the acetylcholinesterase (AChE) enzyme.

• Offending Agents: Organophosphate pesticides (chlorpyrifos, malathion), carbamate insecticides (carbaryl, propoxur), chemical nerve agents (sarin, VX, tabun, soman), Alzheimer pharmaceuticals (donepezil, rivastigmine), and cholinergic therapeutic drugs (physostigmine, neostigmine, pilocarpine, bethanechol).
• Muscarinic Overstimulation (The SLUDGEM / DUMBELS Constellation):
  • Diaphoresis / Diarrhea
  • Urination (incontinence due to detrusor contraction and trigone relaxation)
  • Miosis (pinpoint pupils, ciliary spasm)
  • Bradycardia, Bronchorrhea, Bronchospasm (the lethal 'Killer B's')
  • Emesis (violent gastrointestinal cramping and vomiting)
  • Lacrimation (profuse tearing)
  • Salivation (uncontrollable drooling)
• Nicotinic Overstimulation (Autonomic Ganglia and Neuromuscular Junction):
  • Mnemonic MTWTF: Mydriasis (early sympathetic ganglionic firing), Tachycardia, Weakness, Tremors, Fasciculations (visible muscle twitching of the eyelids, tongue, and calves progressing to diaphragmatic fatigue and flaccid paralysis).
• Central Nervous System: Anxiety, restlessness, confusion, central apnea, coma, and intractable status epilepticus.

3. Sympathomimetic Toxidrome

Sympathomimetic toxicity is driven by excessive stimulation of alpha- and beta-adrenergic receptors via endogenous catecholamine release, direct adrenergic agonism, or inhibition of catecholamine reuptake.

• Offending Agents: Cocaine, amphetamines, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA / 'Ecstasy'), synthetic cathinones ('bath salts'), ephedrine, pseudoephedrine, phenylephrine, methylphenidate, and high-dose caffeine or theophylline.
• Pathophysiological Manifestations:
  • Vital Signs: Moderate to severe sinus tachycardia, marked systemic hypertension, hyperthermia, and tachypnea.
  • Neurologic: Hyperalertness, paranoia, acute psychomotor agitation, hyperreflexia, tremors, and seizures.
  • Ocular: Bilateral mydriasis with preserved light reflex.
  • Cutaneous & Gastrointestinal: Profuse, generalized diaphoresis (warm, drenching sweat) and hyperactive, audible bowel sounds with abdominal cramping or diarrhea.

4. Opioid Toxidrome

Opioid poisoning is mediated through activation of central and peripheral opioid receptors, predominantly μ-receptors, which inhibit adenylyl cyclase, hyperpolarize neurons via potassium channels, and depress presynaptic neurotransmitter release.

• Offending Agents: Morphine, heroin, oxycodone, hydrocodone, methadone, fentanyl and novel synthetic fentanyl analogues, buprenorphine, hydromorphone, and tramadol.
• Pathophysiological Manifestations (The Cardinal Triad):
  1. Central Nervous System Depression: Ranging from somnolence to unarousable coma.
  2. Respiratory Depression: Marked reduction in respiratory rate (< 10 to 12 breaths/min) and tidal volume, progressing to hypoxemic respiratory arrest and secondary anoxic brain injury.
  3. Miosis: Pinpoint pupils (symmetric, 1–2 mm, responsive to high-intensity light).
• Exceptions to Miosis: Mydriasis or normal pupil size can occur with meperidine (normeperidine anticholinergic properties), propoxyphene, tramadol, severe concurrent hypoxia/hypothermia, or co-ingestion of sympathomimetics.
• Associated Findings: Hypothermia, bradycardia, hypotension, diminished bowel sounds, and non-cardiogenic pulmonary edema (especially with heroin, methadone, or high-potency synthetic opioids).

5. Sedative-Hypnotic Toxidrome

Sedative-hypnotic toxicity is characterized by global depression of central nervous system cortical and subcortical function, most commonly mediated through potentiation of gamma-aminobutyric acid (GABAA) neurotransmission.

• Offending Agents: Benzodiazepines (diazepam, lorazepam, alprazolam), barbiturates (phenobarbital, butalbital), non-benzodiazepine receptor agonists / 'Z-drugs' (zolpidem, zopiclone, eszopiclone), ethanol, carisoprodol, meprobamate, and gamma-hydroxybutyrate (GHB).
• Pathophysiological Manifestations:
  • Neurologic: Somnolence, stupor, coma, dysarthria (slurred speech), prominent cerebellar ataxia, nystagmus (horizontal, vertical, or rotatory), and diminished deep tendon reflexes.
  • Vital Signs: Typically marked by stable or only mildly depressed vital signs (mild bradycardia and borderline hypotension). In pure oral benzodiazepine overdose, significant respiratory depression is rare unless co-ingested with other central depressants or administered intravenously.
  • Ocular: Pupils are typically normal in size (mid-position) and reactive, contrasting with the pinpoint pupils of opioid overdose.
  • Barbiturate Nuances: Severe barbiturate overdose can produce profound coma resembling brain death (absent brainstem reflexes, electroencephalographic silence, hypothermia, flaccid paralysis) and cutaneous bullous lesions ('barbiturate blisters') over pressure points.

---

The Critical Differentiation Matrix: Anticholinergic vs. Sympathomimetic

Both anticholinergic and sympathomimetic overdoses present with an 'adrenergic-like' hyperdynamic physiological state: tachycardia, hypertension, hyperthermia, agitation, and mydriasis. Differentiating these two entities at the bedside is critical, as their management pathways diverge significantly (e.g., physostigmine administration for pure anticholinergic delirium versus aggressive benzodiazepine sedation and cooling for sympathomimetics).

The Core Diagnostic Hallmark: "WET vs. DRY"
Sympathomimetic = WET (Diaphoresis, Moist Axillae, Hyperactive Bowel Sounds)
Anticholinergic = DRY (Anhidrosis, Parched Axillae, Absent Bowel Sounds, Urinary Retention)

Systematic Comparison Table

Bedside Examination Pearl: Always check the patient's axillary vaults. In a patient with tachycardia, fever, and wide pupils, finding soaking wet axillae excludes pure anticholinergic toxicity and confirms sympathomimetic or serotonergic etiology. Conversely, dry axillae provide near-conclusive proof of anticholinergic muscarinic receptor blockade.

---

Mixed Toxidromes and Polypharmacy

In acute intentional self-poisoning, simultaneous ingestion of multiple xenobiotics is exceptionally common. When substances from different classes are combined, their physiological effects may antagonize, synergize, or sequentially unmask one another.

1. Opposing Vectors (Antagonism and Masking)

• Opioid + Sympathomimetic ('Speedball' / Fentanyl + Methamphetamine): The respiratory depression and pupillary constriction of the opioid may mask the hyperadrenergic tachypnea and mydriasis of the stimulant. However, as the shorter-acting xenobiotic metabolizes—or if naloxone is administered—the uninhibited stimulant toxicity emerges abruptly, precipitating severe hypertensive crises, hyperpyrexia, and extreme agitation.
• Sedative-Hypnotic + Anticholinergic: Co-ingestion of a benzodiazepine with diphenhydramine can blunt the classic muttering delirium of anticholinergic toxicity, presenting merely as somnolence. However, peripheral markers—tachycardia, dry skin, and urinary retention—persist and reveal the occult antimuscarinic component.

2. Synergistic Vectors (Compounding Toxicity)

• Opioid + Benzodiazepine + Ethanol: Produces profound, supra-additive respiratory and central nervous system depression. Doses of each individual agent that would be well tolerated in isolation become collectively fatal.
• TCA + Antihistamine + Antipsychotic: Produces devastating compounding anticholinergic burden combined with ventricular conduction delays (sodium channel blockade) and QTc prolongation.

3. Kinetic Divergence and Sequential Unmasking

Differences in absorption kinetics, protein binding, volume of distribution, and elimination half-lives cause clinical presentations to shift over time:

• In a mixed overdose of an immediate-release benzodiazepine and an extended-release theophylline, the patient initially presents in deep sedative-hypnotic coma. As the benzodiazepine is metabolized and the extended-release theophylline reaches peak serum concentrations at 12 to 18 hours, the patient abruptly transitions into refractory tachyarrhythmias and status epilepticus.

---

Vital Sign Diagnostic Pattern Analysis

Vital signs are the single most sensitive real-time monitor of toxicological pathology. Organizing toxicological differentials by vital sign pairs allows rapid, algorithmic diagnostic categorization.

1. The Bradycardia + Hypotension Differential: The PACED Mnemonic

Concurrent depression of heart rate (< 60 bpm) and systolic blood pressure (< 90 mmHg) represents toxicological shock. Five major pharmacological classes account for the vast majority of presentations:

P - Propranolol (and other Beta-Adrenergic Antagonists)
A - Anticholinesterases (Organophosphates, Carbamates) / Alpha-2 Agonists (Clonidine, Guanfacine)
C - Calcium Channel Blockers (Verapamil, Diltiazem)
E - Ethanol and Sedative-Hypnotics (Barbiturates, GHB)
D - Digoxin and Cardiac Glycosides

2. The Tachycardia + Hypertension Differential

Toxicological excitation states presenting with heart rate > 100 bpm and systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg fall into four primary categories:

1. Sympathomimetic Ingestion: Cocaine, amphetamines, cathinones, ephedrine (diaphoretic skin, hyperactive bowels).
2. Anticholinergic Ingestion: Antihistamines, tricyclics, atropine, plant alkaloids (anhidrotic skin, absent bowels, urinary retention).
3. Central Withdrawal Syndromes: Abrupt cessation of ethanol, benzodiazepines, barbiturates, or central alpha-2 agonists (clonidine rebound). Accompanied by gross motor tremor, diaphoresis, auditory/visual hallucinations, and preserved pupil size.
4. Hypermetabolic Toxins: Salicylates (early uncoupling of oxidative phosphorylation), theophylline, caffeine, monoamine oxidase inhibitor (MAOI) interactions with tyramine or serotonergic drugs.

3. Temperature Extremes in Clinical Toxicology

Hypothermia (< 35.0°C / 95.0°F)  vs.  Hyperthermia (> 38.3°C / 101.0°F, Severe > 40.0°C / 104.0°F)
Depressants & Vasodilators            Metabolic Uncouplers, Adrenergic & Serotonergic Crises

• Hypothermia (< 35.0°C):
  • Mechanisms: Impairment of central thermoregulation in the preoptic anterior hypothalamus, peripheral vasodilation increasing radiant heat loss, and prolonged immobility in cold ambient environments.
  • Etiologies: Ethanol, opioids, barbiturates, benzodiazepines, clonidine, phenothiazines (chlorpromazine impairs hypothalamic shivering responses), and oral hypoglycemic agents inducing neuroglycopenia.
• Hyperthermia (> 38.3°C, critical toxicity > 40.0°C):
  • Mechanisms: Uncontrolled skeletal muscle hyperactivity (rigidity, tremor, seizures), peripheral anhidrosis preventing evaporative heat dissipation, and direct biochemical uncoupling of mitochondrial oxidative phosphorylation.
  • Etiologies & Syndromic Differentiation:
    • Sympathomimetics: Excessive psychomotor agitation and vasoconstriction.
    • Anticholinergics: Inability to sweat ('hot as a hare') with retained internal metabolic heat.
    • Salicylates & Dinitrophenol: Uncoupling of mitochondrial oxidative phosphorylation; ATP generation ceases and energy dissipates entirely as heat.
    • Serotonin Syndrome (Hunter Criteria): Marked neuromuscular excitation (spontaneous clonus, inducible clonus, ocular clonus, tremor, hyperreflexia) predominantly affecting lower extremities, diaphoresis, and hyperthermia.
    • Neuroleptic Malignant Syndrome (NMS): Dopamine D₂ receptor blockade producing generalized severe 'lead-pipe' muscle rigidity, bradykinesia, profound hyperthermia, and fluctuating autonomic instability developing over days rather than hours.

---

Poison Center Case Scenario: The Agitated Adolescent with Hallucinations

A 16-year-old high school student is transported to the emergency department after being found in his bedroom by his parents. He was shouting incoherently, picking at unseen bugs in the air, and unable to recognize his family. Physical examination reveals blood pressure 146/92 mmHg, heart rate 138 bpm, respiratory rate 22 breaths/min, and oral temperature 38.4°C (101.1°F). The pupils are 7 mm and minimally reactive. The emergency physician contacts the poison center believing the patient has ingested MDMA or methamphetamine and requests guidance on starting an intravenous beta-blocker for hypertension.

Specialist in Poison Information Interventions

1. Diagnostic Clarification: The CSPI directs the bedside physician to immediately examine the patient's axillary vaults and perform an abdominal / bladder examination.
2. Physical Findings Reported: The physician palpates the axillae and finds them completely dry; auscultation of the abdomen reveals total silence with zero bowel sounds over 2 minutes; a bedside ultrasound identifies a massively distended urinary bladder containing 950 mL of urine.
3. Toxidrome Identification: The CSPI explains that dry axillae, silent bowel sounds, and severe urinary retention definitively exclude sympathomimetic toxicity and confirm an anticholinergic toxidrome (subsequently identified as an intentional ingestion of 30 tablets of diphenhydramine 25 mg).
4. Countering Dangerous Management: The CSPI strongly cautions against administering beta-blockers, which would produce unopposed alpha-adrenergic vasoconstriction in sympathomimetic states and fail to address the underlying antimuscarinic mechanism. Instead, the CSPI recommends placing a urinary catheter, administering intravenous benzodiazepines for agitation, and evaluating criteria for physostigmine administration.